ORPHAZYME A/S

ORPHA
Real-time Estimate Quote. Real-time Estimate  - 12/02 10:36:00 am
19.49DKK -9.35%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Number of employees : 141 people.
Managers
Name Title
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus Bornæs Senior Manager-Research & Development
Thomas Blaettler Chief Medical Officer
Martin N. Bonde Independent Director
Catherine Moukheibir Independent Director
Carrolee Barlow Independent Director
Bo Jesper Hansen Deputy Chairman
Shareholders
Name Equities %
Orpha Pooling BV 2,431,672 6.96%
Sunstone Capital A/S 1,789,845 5.12%
Aescap Venture Management BV 1,758,105 5.03%
Danske Bank A/S (Investment Management) 1,717,536 4.91%
Consonance Capital Management LP 1,339,909 3.83%
Rémi Droller 905,525 2.59%
Handelsbanken Fonder AB 739,810 2.12%
SPSW Capital GmbH 586,000 1.68%
Fjärde AP-fonden 534,285 1.53%
LSP Management Group BV 279,157 0.80%
Company contact information
Orphazyme A/S
Ole Maaløes Vej 3
Copenhagen, Capital Region 2200

Phone : +45.39.17.82.72
Web : http://www.orphazyme.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ORPHAZYME A/S-72.88%114
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.30.33%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122
BEIGENE, LTD.36.22%32 911
GENMAB A/S3.82%25 598
ARGENX SE3.26%14 579
ACCELERON PHARMA INC.39.71%10 932
HUALAN BIOLOGICAL ENGINEERING INC.-32.50%8 168
ASCENDIS PHARMA A/S-15.09%8 033
NEUROCRINE BIOSCIENCES, INC.-13.15%7 664
MIRATI THERAPEUTICS, INC.-39.88%7 291
SAREPTA THERAPEUTICS, INC.-51.79%7 157
ARROWHEAD PHARMACEUTICALS, INC.-12.68%7 003
GW PHARMACEUTICALS PLC89.72%6 907
LEGEND BIOTECH CORPORATION76.99%6 629
REMEGEN CO., LTD.8.95%6 507
BIOCON LIMITED-20.35%5 892
MARAVAI LIFESCIENCES HOLDINGS, INC.54.87%5 711
Brand Portfolio
» More brands of Orphazyme A/S